Invivyd Inc. Market Cap ($186.76 Million)
Market Cap & Net Worth: Invivyd Inc. (IVVD)
Invivyd Inc. market cap. Invivyd Inc. (NASDAQ:IVVD) has a market capitalization of $186.76 Million ($186.76 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16613 globally and #3958 in its home market, demonstrating a 7.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Invivyd Inc.'s stock price $0.63 by its total outstanding shares 294758746 (294.76 Million). Also see cash efficiency ratio of Invivyd Inc. for how efficiently the company converts equity into cash flow.
Invivyd Inc. Market Cap History (2021–2026)
Invivyd Inc. market cap history from 2021 to 2026. Data shows change from $2.14 Billion to $186.76 Million (-48.62% CAGR). Check Invivyd Inc. (IVVD) stock price for real-time trading data and today's change.
Index Memberships
Invivyd Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #451 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1633 of 3165 |
Weight: Invivyd Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Invivyd Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Invivyd Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Invivyd Inc. (IVVD) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
13.63x
Invivyd Inc.'s market cap is 13.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $130.61 Million | $25.38 Million | -$169.93 Million | 5.15x | N/A |
| 2025 | $728.05 Million | $53.43 Million | -$52.49 Million | 13.63x | N/A |
Competitor Companies of IVVD by Market Capitalization
Companies near Invivyd Inc. in the global market cap rankings as of November 5, 2026. Also see IVVD total assets for a full breakdown of the balance sheet.
Key companies related to Invivyd Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Invivyd Inc. (2021–2026)
Market capitalization of Invivyd Inc. from 2021 to today. Between 2021 and today, Invivyd Inc.'s market cap moved from $2.14 Billion to $ 186.76 Million, with a yearly change of -48.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $186.76 Million | -74.35% |
| 2025 | $728.05 Million | +457.44% |
| 2024 | $130.61 Million | -88.75% |
| 2023 | $1.16 Billion | +162.67% |
| 2022 | $442.14 Million | -79.34% |
| 2021 | $2.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Invivyd Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $186.76 Million USD |
| MoneyControl | $186.76 Million USD |
| MarketWatch | $186.76 Million USD |
| marketcap.company | $186.76 Million USD |
| Reuters | $186.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more